Capital Invest - Medical Consulting 

Capital investors face increasing challenges regarding risk reduction and return on investment. Since classical/conservative investments are often not associated with a high margin of ROI, biotechnology is gaining popularity.

However, many investors consider investments in biotechnology to constitute high-risk investments unless these investors do have experts in biotechnology analysing the portfolio, risks and chances of the respective candidate companies. 

Dr Jürs offers personalised and tailored medical-scientific analysis packages for each investor, so please be so kind as to contact Dr Jürs directly to discuss suitable packages.